Out of limbo: a toolbox to eliminate ambiguity around HDAC6, offering a novel therapeutic opportunity against multiple myeloma. Ghent University
HDAC6 is an enzyme with a wide variety of substrates and interaction partners, which makes it an important regulator of diverse cellular processes and, in case of aberrant function, an actor in several diseases including cancer, neurodegenerative disorders and inflammation. Therefore, inhibitors have been developed to selectively target HDAC6. However, these compounds only target the deacetylase catalytic cavity, while also a ubiquitin ...